TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant.
Aicha E QuamineNicholas R MohrdieckChloe A KingAnastasia A GriggsJillian M KlineMonica Moonkyung ChoSean P RinellaKatharine E TippinsPaul D BatesLei ShiLongzhen SongNicholas J HessTyce J KearlBryon D JohnsonChristian M CapitiniPublished in: bioRxiv : the preprint server for biology (2024)
Allo-HCT can be a platform for treating NBL using combination ex-vivo stimulated allogeneic NK cell therapy with TIM-3 blockade to enhance the GVT effect without inducing GVHD.
Keyphrases
- cell therapy
- nk cells
- stem cell transplantation
- bone marrow
- mesenchymal stem cells
- stem cells
- hematopoietic stem cell
- acute lymphoblastic leukemia
- high dose
- acute myeloid leukemia
- diffuse large b cell lymphoma
- allogeneic hematopoietic stem cell transplantation
- multiple myeloma
- high throughput
- hodgkin lymphoma
- single cell
- low dose
- cell cycle arrest
- cell proliferation
- cell death